OBJECTIVE: To analyze the essential oils from flowers, leaves, stems, roots, and fruits of Chaihu(Radix Bupleuri Chinensis).METHODS: We extracted essential oils from different parts of Chaihu(Radix Bupleuri Chinensis)...OBJECTIVE: To analyze the essential oils from flowers, leaves, stems, roots, and fruits of Chaihu(Radix Bupleuri Chinensis).METHODS: We extracted essential oils from different parts of Chaihu(Radix Bupleuri Chinensis) using a steam distillation method. The essential oils were analyzed by gas chromatography-mass spectrometry(GC-MS). Data were collected in full scan mode(m/z 60-600). Volatile components were identified based on their retention indices and by comparing their mass spectra with those in the National Institute of Standards and Technology 2005 database assisted by tandem mass spectrometry information. The relative content of each constituent wasdetermined by area normalization.RESULTS: We identified 111 components, of which12 were common to all 5 parts, 30 were found only in roots, 14 were found only in flowers, 6 were found only in leaves, 4 were found only in stems,and 17 were found only in fruits.CONCLUSION: Our results show that the stems,flowers, leaves, and fruits of Chaihu(Radix Bupleuri Chinensis)contain a high concentration of essential oils, and that the exact composition of the essential oils differs among the plant parts. To develop new medicines and make full use of the Chaihu(Radix Bupleuri Chinensis)resource, it is important to characterize the essential oils from different parts of the plant. In future research, it will be important to determine the pharmacological effects of the various components and the essential oil mixtures.展开更多
Background:The standard first-line treatment for human epidermal growth factor receptor 2(HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel.This study aimed...Background:The standard first-line treatment for human epidermal growth factor receptor 2(HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel.This study aimed to evaluate the effectiveness of KN026,an anti-HER2 bispecific antibody,plus docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer.Methods:This open-label,single-arm,phase II study enrolled patients with HER2-positive recurrent/metastatic breast cancer in 19 centers across China from December 30,2019 to May 27,2021.Patients were administered KN026(30 mg/kg)plus docetaxel(75 mg/m2)in 21-day cycles.Primary endpoints included the objective response rate(ORR)and duration of response(DOR).In addition,overall survival(OS),progression-free survival(PFS),clinical benefit rate(CBR)and safety profile were examined.Results:A total of 57 patients were included.In the efficacy analysis set of 55 patients,the ORR was 76.4%(95%confidence interval[CI],63.0%-86.8%),and the CBR was 85.5%(95%CI,73.3%-93.5%).The median DOR was not reached(95%CI,20.7 months-not reached).In the safety set of 57 patients,the median PFS was 27.7 months(95%CI,18.0 months-not reached).The median OS was not reached,with OS rates at 12,24 and 30 months of 93.0%,84.1%and 78.5%,respectively.Grade≥3 treatment-emergent adverse events(AEs)were detected in 36(63.2%)patients.No deaths were attributed to KN026 or docetaxel.Conclusion:KN026 plus docetaxel showed promising efficacy and a manageable safety profile in first-line treatment of HER2-positive recurrent/metastatic breast cancer.展开更多
基金Breeding Research Project of Chinese Medical Herbs in Sichuan Province:Study on the breeding of new Chaihu variety and cultivation and the related techniques(No.2011NZ0098-12-11)China Spark Program in 2010(No.2010GA810056)
文摘OBJECTIVE: To analyze the essential oils from flowers, leaves, stems, roots, and fruits of Chaihu(Radix Bupleuri Chinensis).METHODS: We extracted essential oils from different parts of Chaihu(Radix Bupleuri Chinensis) using a steam distillation method. The essential oils were analyzed by gas chromatography-mass spectrometry(GC-MS). Data were collected in full scan mode(m/z 60-600). Volatile components were identified based on their retention indices and by comparing their mass spectra with those in the National Institute of Standards and Technology 2005 database assisted by tandem mass spectrometry information. The relative content of each constituent wasdetermined by area normalization.RESULTS: We identified 111 components, of which12 were common to all 5 parts, 30 were found only in roots, 14 were found only in flowers, 6 were found only in leaves, 4 were found only in stems,and 17 were found only in fruits.CONCLUSION: Our results show that the stems,flowers, leaves, and fruits of Chaihu(Radix Bupleuri Chinensis)contain a high concentration of essential oils, and that the exact composition of the essential oils differs among the plant parts. To develop new medicines and make full use of the Chaihu(Radix Bupleuri Chinensis)resource, it is important to characterize the essential oils from different parts of the plant. In future research, it will be important to determine the pharmacological effects of the various components and the essential oil mixtures.
文摘Background:The standard first-line treatment for human epidermal growth factor receptor 2(HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel.This study aimed to evaluate the effectiveness of KN026,an anti-HER2 bispecific antibody,plus docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer.Methods:This open-label,single-arm,phase II study enrolled patients with HER2-positive recurrent/metastatic breast cancer in 19 centers across China from December 30,2019 to May 27,2021.Patients were administered KN026(30 mg/kg)plus docetaxel(75 mg/m2)in 21-day cycles.Primary endpoints included the objective response rate(ORR)and duration of response(DOR).In addition,overall survival(OS),progression-free survival(PFS),clinical benefit rate(CBR)and safety profile were examined.Results:A total of 57 patients were included.In the efficacy analysis set of 55 patients,the ORR was 76.4%(95%confidence interval[CI],63.0%-86.8%),and the CBR was 85.5%(95%CI,73.3%-93.5%).The median DOR was not reached(95%CI,20.7 months-not reached).In the safety set of 57 patients,the median PFS was 27.7 months(95%CI,18.0 months-not reached).The median OS was not reached,with OS rates at 12,24 and 30 months of 93.0%,84.1%and 78.5%,respectively.Grade≥3 treatment-emergent adverse events(AEs)were detected in 36(63.2%)patients.No deaths were attributed to KN026 or docetaxel.Conclusion:KN026 plus docetaxel showed promising efficacy and a manageable safety profile in first-line treatment of HER2-positive recurrent/metastatic breast cancer.
